Several pharmaceutical companies have recently said they’ll delay some of their price increases, under pressure from the Trump administration. But hospitals have made no such concessions, even though they make up a much larger share of total health care spending.
The bottom line: Axios reached out to 27 hospital systems, many of which have some of the highest charges in the country. All of them were silent about whether they would lower or hold off on price increases.
Driving the news: Pfizer, Novartis, Merck and other drug makers have said they will delay, freeze or roll back price increases on some of their medicines.
- Experts largely dismissed those pledges as political bandages with little real effect on patients’ pocketbooks. But President Trump’s ability to publicly pressure drugmakers into even those steps is still noteworthy.
The big picture: Drug pricing is the political controversy of the moment, but hospitals cost the health care system far more.
- Retail drug spending represents 10% of U.S. health care spending, while hospital and doctor services consume about half of spending.
- Health care prices have grown somewhat slowly over the past few years. But slow growth of high prices still leaves high prices.
- Hospitals’ sticker prices, like the list prices of drugs, are not indicative of what most people pay, but they are still important when it comes to negotiating with commercial health insurers.
- A major difference worth highlighting is that Medicare sets its own fixed payment rates for hospital services, but does not have that power over prescription drugs.
What we’re hearing: Almost nothing from the hospital industry.
Axios reached out to 27 hospital systems that have some of the highest charges in the country, according to federal data.